Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 413,437
  • Shares Outstanding, K 63,802
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,950 K
  • 60-Month Beta 0.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.97
Trade LRMR with:

Options Overview Details

View History
  • Implied Volatility 122.28% ( +1.10%)
  • Historical Volatility 87.35%
  • IV Percentile 82%
  • IV Rank 43.19%
  • IV High 280.65% on 02/09/24
  • IV Low 1.89% on 11/14/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 190
  • Volume Avg (30-Day) 185
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 9,328
  • Open Int (30-Day) 7,623

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.29
  • Low Estimate -0.42
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -76.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.07 +8.81%
on 10/02/24
8.21 -19.55%
on 09/09/24
-1.45 (-17.95%)
since 09/06/24
3-Month
6.07 +8.81%
on 10/02/24
11.20 -41.03%
on 07/16/24
-1.58 (-19.35%)
since 07/08/24
52-Week
2.18 +202.98%
on 11/10/23
13.68 -51.72%
on 02/15/24
+3.13 (+90.35%)
since 10/06/23

Most Recent Stories

More News
Larimar: Q2 Earnings Snapshot

Larimar: Q2 Earnings Snapshot

LRMR : 6.66 (+2.78%)
2 Potentially High-Reward Growth Stocks to Buy Right Now

These two biotechnology stocks could be gearing up for a run.

RNA : 45.32 (+3.12%)
LRMR : 6.66 (+2.78%)
Stock Index Futures Mixed Ahead of More Fed Speak, Nvidia Earnings Awaited

June S&P 500 E-Mini futures (ESM24) are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.08% this morning as investors awaited further comments from Federal Reserve officials while also...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
NCLH : 20.89 (+3.98%)
MU : 102.31 (-0.58%)
NVDA : 131.82 (+3.21%)
JPM : 208.96 (-0.93%)
LOW : 271.87 (+1.24%)
AZO : 3,045.65 (-0.26%)
TOL : 151.14 (+0.43%)
M : 15.27 (-0.59%)
URBN : 36.47 (+0.03%)
SFSN.Z.EB : 128.600 (+0.31%)
Larimar: Q1 Earnings Snapshot

Larimar: Q1 Earnings Snapshot

LRMR : 6.66 (+2.78%)
Larimar: Q4 Earnings Snapshot

Larimar: Q4 Earnings Snapshot

LRMR : 6.66 (+2.78%)
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.

BIIB : 182.72 (-0.34%)
XBI : 97.19 (+0.89%)
XLK : 226.54 (+1.25%)
OCUL : 9.50 (+0.21%)
LRMR : 6.66 (+2.78%)
Larimar: Q3 Earnings Snapshot

Larimar: Q3 Earnings Snapshot

LRMR : 6.66 (+2.78%)
Larimar: Q2 Earnings Snapshot

Larimar: Q2 Earnings Snapshot

LRMR : 6.66 (+2.78%)
Larimar: Q1 Earnings Snapshot

Larimar: Q1 Earnings Snapshot

LRMR : 6.66 (+2.78%)
Larimar: Q4 Earnings Snapshot

Larimar: Q4 Earnings Snapshot

LRMR : 6.66 (+2.78%)

Business Summary

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

See More

Key Turning Points

3rd Resistance Point 7.17
2nd Resistance Point 6.97
1st Resistance Point 6.72
Last Price 6.66
1st Support Level 6.27
2nd Support Level 6.07
3rd Support Level 5.82

See More

52-Week High 13.68
Fibonacci 61.8% 9.29
Fibonacci 50% 7.93
Last Price 6.66
Fibonacci 38.2% 6.57
52-Week Low 2.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar